Doehn C, Siebels M, Steiner T
Urologikum Lübeck, Am Kaufhof 2, 23566, Lübeck, Deutschland.
Urologische Gemeinschaftspraxis Pasing, München, Deutschland.
Urologe A. 2020 Feb;59(2):162-168. doi: 10.1007/s00120-020-01126-8.
Renal cell carcinoma is the third most common tumor of the genitourinary system. Small tumors are increasingly treated by nephron-sparing surgery, focal therapy via cryoablation or radiofrequency ablation and also active surveillance. These treatment options are associated with increased follow-up care.
What are the current recommendations on follow-up care for different therapeutic approaches in renal cell carcinoma?
We analyzed different biological aspects regarding renal cell carcinoma, diagnostic procedures as well as recommendations of current guidelines (e.g. German S3, EAU AUA).
Follow-up of renal cell carcinoma is not well standardized due to the limited amount of data. In general, follow-up should be intensified during the first 3 years following initial therapy as well as in patients with increased risk for tumor recurrence. For risk calculation different prognostic models based on clinical parameters have been published.
Current recommendations on follow-up care in renal cell carcinoma are based on retrospective studies. Future strategies must include markers and be studied in a prospective manner.
肾细胞癌是泌尿生殖系统中第三常见的肿瘤。小肿瘤越来越多地通过保留肾单位手术、冷冻消融或射频消融的局部治疗以及主动监测来治疗。这些治疗选择与增加的随访护理相关。
对于肾细胞癌不同治疗方法的随访护理，当前的建议是什么？
我们分析了肾细胞癌的不同生物学方面、诊断程序以及当前指南（如德国S3、欧洲泌尿外科学会、美国泌尿外科学会）的建议。
由于数据量有限，肾细胞癌的随访尚未得到很好的标准化。一般来说，在初始治疗后的前3年以及肿瘤复发风险增加的患者中，随访应加强。为了进行风险计算，已经发表了基于临床参数的不同预后模型。
当前关于肾细胞癌随访护理的建议基于回顾性研究。未来的策略必须包括标志物，并以前瞻性方式进行研究。
